Department of General Pediatrics, Denver Health Medical Center, Denver, CO, USA.
Department of General Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2180971. doi: 10.1080/21645515.2023.2180971. Epub 2023 Mar 9.
Vaccination for Human Papillomavirus (HPV) is important to reduce rates of cervical and oropharyngeal cancer. We aimed to evaluate if a program to initiate HPV vaccination at 9 years improved initiation and completion rates by 13 years of age. Data on empaneled patients aged 9-13 years from January 1, 2021 to August 30, 2022 were abstracted from the electronic health record. Primary outcome measures included HPV vaccination initiation and series completion by 13 years of age. The secondary outcome measure was missed opportunities for HPV vaccination. In total, 25,888 patients were included (12,433 pre-intervention, and 13,455 post-intervention). The percentage of patients aged 9-13 with an in-person visit who received at least 1 dose of HPV vaccine increased from 30% pre-intervention to 43% post-intervention. The percentage of patients who received 2 doses of vaccine increased from 19.3% pre-intervention to 42.7% post-intervention. For the overall population seen in-person, initiation of HPV vaccination by age 13 years increased from 42% to 54%. HPV completion increased as well (13% to 18%). HPV vaccination initiation at 9 years of age may be an acceptable and effective approach to improving vaccination rates.
接种人乳头瘤病毒 (HPV) 疫苗对于降低宫颈癌和口咽癌的发病率非常重要。我们旨在评估在 9 岁时启动 HPV 疫苗接种计划是否能提高 13 岁时的接种起始率和完成率。从 2021 年 1 月 1 日至 2022 年 8 月 30 日,从电子健康记录中提取了 9-13 岁入组患者的数据。主要结局指标包括 13 岁时 HPV 疫苗接种起始率和系列完成率。次要结局指标是 HPV 疫苗接种的错失机会。共有 25888 名患者入选(12433 名干预前,13455 名干预后)。在接受面对面就诊的 9-13 岁患者中,至少接种一剂 HPV 疫苗的患者比例从干预前的 30%增加到干预后的 43%。接种两剂疫苗的患者比例从干预前的 19.3%增加到干预后的 42.7%。对于接受面对面就诊的所有患者,13 岁时 HPV 疫苗接种起始率从 42%增加到 54%。HPV 完成率也有所提高(从 13%增加到 18%)。在 9 岁时接种 HPV 疫苗可能是一种可接受且有效的提高疫苗接种率的方法。